MXCT today
$1.19+$0.00 (+0.00%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourBullish
15 minDescending Triangle
5 minSymmetric Triangle
Daily trend turns up above $1.86
Key levels
Resistance$1.54
Resistance$1.25
Support$1.08
Support$0.94
Latest news & SEC filings
EarningsMaxCyte Discusses Third-Quarter 2026 Results on Conference Call
EarningsMaxCyte lifts FY revenue outlook with Q3 2026 numbers out
DealMaxCyte agrees to buy Akron BioProducts in $151.8 million deal
GuidanceMaxCyte forecasts FY2026 revenue above $34.5 million, exceeding $32.211 million estimate
All MXCT news →About MaxCyte
MaxCyte is a cell engineering company that provides platform technologies for developing cell and gene therapies. Its ExPERT platform, based on Flow Electroporation, includes instruments, single-use processing assemblies, and consumables used to deliver molecules into cells. Customers include biopharmaceutical companies, biotechnology firms, and academic and government research institutions. The company operates in the United States and other countries and licenses its technology to cell therapy developers.
Based on the company's 10-K filed Mar 25, 2026.
Nasdaq · Healthcare
MAXCYTE, INC. (MXCT)
What Is the Price Target for MXCT?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is MXCT a Buy or Sell Right Now?
Thesis
- •Revenue growing -14.5% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MXCT.
Start Free Trial →Is MXCT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$3.85
30
Moat Score
NONE
2/9
Piotroski Score
0.7
Altman Z-Score
What Is Smart Money Doing with MXCT?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MXCT Growth Story
Revenue YoY
-14.5%
3yr Revenue CAGR
-9.3%
EPS Growth YoY
-7.69%
FCF Growth YoY
-23.6%
Revenue Trend
DECLINING
Dark Pool Trades for MXCT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MXCT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:00 | $1.19 | 1,004 | $$1K | SELL |
| 20:59:34 | $1.20 | 8,000 | $$10K | BUY |
| 20:59:27 | $1.19 | 1,000 | $$1K | SELL |
| 20:56:49 | $1.17 | 2,748 | $$3K | SELL |
| 20:39:42 | $1.16 | 3,841 | $$4K | BUY |
5 dark pool trades shown · $$20K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for MAXCYTE, INC. (MXCT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MXCT — frequently asked questions
What is MXCT stock price today?
MAXCYTE, INC. (MXCT) is at $1.19, up 0.00% (+$0.00) at the Nov 13, 2026 close.
Why is MXCT stock moving today?
Latest MXCT news — Nov 10, 2026: MaxCyte Discusses Third-Quarter 2026 Results on Conference Call · Nov 10, 2026: MaxCyte lifts FY revenue outlook with Q3 2026 numbers out
Why did MXCT stock move on Nov 10, 2026?
MaxCyte shares fell sharply on Tuesday, closing at $1.13, down 19.29% from the open of $1.40, despite a flurry of positive news. The company reported third-quarter 2026 results and lifted its full-year revenue outlook to above $34.5 million, exceeding the $32.211 million estimate, while also announcing a $151.8 million agreement to acquire Akron BioProducts.
What do analysts rate MXCT?
Analyst ratings for MXCT: 5 Buy, 1 Hold, 0 Sell — consensus Strong Buy.
Did MXCT beat earnings?
MXCT last reported on Nov 10, 2026: EPS -$0.05 vs -$0.08 expected — a beat of 37.5%.
Does MXCT pay a dividend?
MXCT does not currently pay a dividend.
What are MXCT support and resistance levels?
Support: $1.08, $0.94, $0.78. Resistance: $1.25, $1.54, $1.76.
What are insiders doing with MXCT?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on MXCT?
Nov 10, 2026: MaxCyte Discusses Third-Quarter 2026 Results on Conference Call · Nov 10, 2026: MaxCyte lifts FY revenue outlook with Q3 2026 numbers out · Nov 10, 2026: MaxCyte agrees to buy Akron BioProducts in $151.8 million deal